EGFR and breast cancer: Among these molecules, copy number gain and overexpression of the 5′‐inositol lipid phosphatase synaptojanin 2 (SYNJ2) in breast cancer provides a paradigmatic example of sustained EGFR activation by altered trafficking pathways.